158 related articles for article (PubMed ID: 36835312)
1. Inguinal Fat Compensates Whole Body Metabolic Functionality in Partially Lipodystrophic Mice with Reduced PPARγ Expression.
Chang CS; Yu SS; Ho LC; Chao SH; Chou TY; Shao AN; Kao LZ; Chang CY; Chen YH; Wu MS; Tsai PJ; Maeda N; Tsai YS
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835312
[TBL] [Abstract][Full Text] [Related]
2. Decreased PPAR gamma expression compromises perigonadal-specific fat deposition and insulin sensitivity.
Tsai YS; Tsai PJ; Jiang MJ; Chou TY; Pendse A; Kim HS; Maeda N
Mol Endocrinol; 2009 Nov; 23(11):1787-98. PubMed ID: 19749155
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor-gamma C190S mutation causes partial lipodystrophy.
Lüdtke A; Buettner J; Wu W; Muchir A; Schroeter A; Zinn-Justin S; Spuler S; Schmidt HH; Worman HJ
J Clin Endocrinol Metab; 2007 Jun; 92(6):2248-55. PubMed ID: 17356052
[TBL] [Abstract][Full Text] [Related]
4. New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.
Lüdtke A; Buettner J; Schmidt HH; Worman HJ
J Med Genet; 2007 Sep; 44(9):e88. PubMed ID: 17766367
[TBL] [Abstract][Full Text] [Related]
5. Familial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor -γ (PPARG) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 Lamin A/C (LMNA) mutations.
Demir T; Onay H; Savage DB; Temeloglu E; Uzum AK; Kadioglu P; Altay C; Ozen S; Demir L; Cavdar U; Akinci B
Diabet Med; 2016 Oct; 33(10):1445-50. PubMed ID: 26756202
[TBL] [Abstract][Full Text] [Related]
6. Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma.
Monajemi H; Zhang L; Li G; Jeninga EH; Cao H; Maas M; Brouwer CB; Kalkhoven E; Stroes E; Hegele RA; Leff T
J Clin Endocrinol Metab; 2007 May; 92(5):1606-12. PubMed ID: 17299075
[TBL] [Abstract][Full Text] [Related]
7. Pparg-P465L mutation worsens hyperglycemia in Ins2-Akita female mice via adipose-specific insulin resistance and storage dysfunction.
Pendse AA; Johnson LA; Tsai YS; Maeda N
Diabetes; 2010 Nov; 59(11):2890-7. PubMed ID: 20724579
[TBL] [Abstract][Full Text] [Related]
8. Fatty acid metabolism in patients with PPARgamma mutations.
Tan GD; Savage DB; Fielding BA; Collins J; Hodson L; Humphreys SM; O'Rahilly S; Chatterjee K; Frayn KN; Karpe F
J Clin Endocrinol Metab; 2008 Nov; 93(11):4462-70. PubMed ID: 18713822
[TBL] [Abstract][Full Text] [Related]
9. Case Report: A New Peroxisome Proliferator-Activated Receptor Gamma Mutation Causes Familial Partial Lipodystrophy Type 3 in a Chinese Patient.
Chen X; Ma Z; Chen P; Song X; Li W; Yu X; Xie J
Front Endocrinol (Lausanne); 2022; 13():830708. PubMed ID: 35422762
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and efficacy of pioglitazone in a Japanese patient with familial partial lipodystrophy due to peroxisome proliferator-activated receptor γ gene mutation.
Iizaka T; Kodama E; Mikura K; Iida T; Imai H; Hashizume M; Kigawa Y; Sugisawa C; Tadokoro R; Endo K; Otsuka F; Isoda M; Ebihara K; Ishibashi S; Nagasaka S
Endocr J; 2023 Jan; 70(1):69-76. PubMed ID: 36171144
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of non-obese diabetic patients with marked insulin resistance identifies a novel familial partial lipodystrophy-associated PPARγ mutation (Y151C).
Visser ME; Kropman E; Kranendonk ME; Koppen A; Hamers N; Stroes ES; Kalkhoven E; Monajemi H
Diabetologia; 2011 Jul; 54(7):1639-44. PubMed ID: 21479595
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor-γ mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system.
Auclair M; Vigouroux C; Boccara F; Capel E; Vigeral C; Guerci B; Lascols O; Capeau J; Caron-Debarle M
Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):829-38. PubMed ID: 23393388
[TBL] [Abstract][Full Text] [Related]
13. Vascular placental abnormalities and newborn death in a pregnant diabetic woman with familial partial lipodystrophy type 3: a possible role for peroxisome proliferator-activated receptor γ.
Castell AL; Hiéronimus S; Lascols O; Fournier T; Fénichel P
Diabetes Metab; 2012 Oct; 38(4):367-9. PubMed ID: 22559930
[TBL] [Abstract][Full Text] [Related]
14. A Pharmacogenetic Approach to the Treatment of Patients With
Agostini M; Schoenmakers E; Beig J; Fairall L; Szatmari I; Rajanayagam O; Muskett FW; Adams C; Marais AD; O'Rahilly S; Semple RK; Nagy L; Majithia AR; Schwabe JWR; Blom DJ; Murphy R; Chatterjee K; Savage DB
Diabetes; 2018 Jun; 67(6):1086-1092. PubMed ID: 29622583
[TBL] [Abstract][Full Text] [Related]
15. Gene-gene and gene-environment interactions in lipodystrophy: Lessons learned from natural PPARγ mutants.
Broekema MF; Savage DB; Monajemi H; Kalkhoven E
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 May; 1864(5):715-732. PubMed ID: 30742913
[TBL] [Abstract][Full Text] [Related]
16. Lessons from human mutations in PPARgamma.
Hegele RA
Int J Obes (Lond); 2005 Mar; 29 Suppl 1():S31-5. PubMed ID: 15711581
[TBL] [Abstract][Full Text] [Related]
17. Fat Mass Reduction With Adipocyte Hypertrophy and Insulin Resistance in Heterozygous PPARγ Mutant Rats.
Gumbilai V; Ebihara K; Aizawa-Abe M; Ebihara C; Zhao M; Yamamoto Y; Mashimo T; Hosoda K; Serikawa T; Nakao K
Diabetes; 2016 Oct; 65(10):2954-65. PubMed ID: 27381370
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor gamma-ligand-binding domain mutations associated with familial partial lipodystrophy type 3 disrupt human trophoblast fusion and fibroblast migration.
Shoaito H; Chauveau S; Gosseaume C; Bourguet W; Vigouroux C; Vatier C; Pienkowski C; Fournier T; Degrelle SA
J Cell Mol Med; 2020 Jul; 24(13):7660-7669. PubMed ID: 32519441
[TBL] [Abstract][Full Text] [Related]
19. Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy.
Akinci B; Onay H; Demir T; Savas-Erdeve Ş; Gen R; Simsir IY; Keskin FE; Erturk MS; Uzum AK; Yaylali GF; Ozdemir NK; Atik T; Ozen S; Yurekli BS; Apaydin T; Altay C; Akinci G; Demir L; Comlekci A; Secil M; Oral EA
Metabolism; 2017 Jul; 72():109-119. PubMed ID: 28641778
[TBL] [Abstract][Full Text] [Related]
20. Natural helix 9 mutants of PPARγ differently affect its transcriptional activity.
Broekema MF; Massink MPG; Donato C; de Ligt J; Schaarschmidt J; Borgman A; Schooneman MG; Melchers D; Gerding MN; Houtman R; Bonvin AMJJ; Majithia AR; Monajemi H; van Haaften GW; Soeters MR; Kalkhoven E
Mol Metab; 2019 Feb; 20():115-127. PubMed ID: 30595551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
